About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Leadership Team

Kevin Pojasek
President and Chief Executive Officer

Sophie Papa
Chief Medical Officer and Head of Translational Science

Board of Directors

Robert Ang Chair
Bauke Anninga Director
Rana Al-Hallaq Director
Josh Resnick Director
Mike Dybbs Director
Kate Bingham Director
Kevin Pojasek President and CEO

Scientific Advisory Board

George Kassiotis, PhD Co-founder of Enara Bio
Francis Crick Institute
Mike Quigley, PhD Sanofi CSO and Global Head of Research
Ex-Gilead and BMS R&D
Drew Pardoll, MD PhD Co-founder of Enara Bio
Johns Hopkins School of Medicine
Eliezer Van Allen, MD PhD Dana-Farber Cancer Institute
Janine Schuurman, PhD Biotech Consultant
Ex-SVP Genmab